May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
In vitro and in vivo Release Profile of a Minimally Invasive Triamcinolone Biodegradable Controlled Release Microspheres System for Intravitreous Use
Author Affiliations & Notes
  • A.G. de Oliveira
    Department of Pharmaceutics, Universidade Estadual Paulista–Unesp, Araraquara , Sao Paulo, Brazil
  • A.A. Silva, Jr
    Department of Pharmaceutics, Universidade Estadual Paulista–Unesp, Araraquara , Sao Paulo, Brazil
  • B. Wanczinski
    Department of Pharmaceutics, Universidade Estadual Paulista–Unesp, Araraquara , Sao Paulo, Brazil
  • J.A. Cardillo
    Department of Ophthalmolgy, Department of Pharmacology,
    Hospital de Olhos de Araraquara, Araraquara , Sao Paulo, Brazil
  • F. Paganelli
    Department of Ophthalmology, Department of Ophthalmolgy,
    Hospital de Olhos de Araraquara, Araraquara , Sao Paulo, Brazil
  • R.A. Costa
    Department of Ophthalmology, Department of Ophthalmolgy,
    Hospital de Olhos de Araraquara, Araraquara , Sao Paulo, Brazil
  • M. Skaf
    Department of Ophthalmolgy, Department of Pharmacology,
    Hospital de Olhos de Araraquara, Araraquara , Sao Paulo, Brazil
  • A.A. Souza–Filho
    Department of Ophthalmolgy, Department of Pharmacology,
    Federal University of Sao Paulo, UNIFESP–EPM, Sao Paulo, Brazil
  • R. Belfort, Jr
    Department of Ophthalmology, Department of Ophthalmolgy,
    Federal University of Sao Paulo, UNIFESP–EPM, Sao Paulo, Brazil
  • B.D. Kuppermann
    Department of Ophthalmolgy, University California Irvine, Irvine, CA
  • Footnotes
    Commercial Relationships  A.G. de Oliveira, None; A.A. Silva Jr, None; B. Wanczinski, None; J.A. Cardillo, None; F. Paganelli, None; R.A. Costa, None; M. Skaf, None; A.A. Souza–Filho, None; R. Belfort Jr, None; B.D. Kuppermann, None.
  • Footnotes
    Support  FAPESP, CNPq, CAPES and PADC Unesp
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3533. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.G. de Oliveira, A.A. Silva, Jr, B. Wanczinski, J.A. Cardillo, F. Paganelli, R.A. Costa, M. Skaf, A.A. Souza–Filho, R. Belfort, Jr, B.D. Kuppermann; In vitro and in vivo Release Profile of a Minimally Invasive Triamcinolone Biodegradable Controlled Release Microspheres System for Intravitreous Use . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3533.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To study a triamcinolone (TR) biodegradable microspheres system (Micro–Taac) for intraocular use proportionating a prolonged drug release with minimal surgical implantation manipulation. Methods: TR and polylactic–co–glycolic acid (PLGA) were dissolved in acetone to obtain the relationship TR/PLGA 1:1 and 1:2. The TR loading efficiency and quantitative analysis were determined by HPLC. The TR microspheres were characterized by scanning electronic microscopy and by diameter measurements. For in vitro studies amounts of microspheres equivalent to 1mg of TR were incubated in phosphate buffer and the analytical concentrations of TR released were determined against the time. For the in vivo studies amounts of microspheres equivalent to 1mg/0.1mL of TR were injected into the vitreous cavity of sixty albino rabbits utilizing a 27–gauge syringe. The TR concentration was determined in the aqueous and vitreous humors up to 120 days. Results: The Micro–Taac showed uniform particle size (1µm +.0.1) distribution. The encapsulated TR in the microspheres was about 39,53 + 1,80%; 33,01 + 1,80 %; for 1:1 and 1:2 TR/PLGA microspheres, respectively. It was verified that the PLGA amounts in the structural material of microparticle play an important role on the rate of TR release. The time required for release of all free TR was 3 hs while for TR/PLGA 1:1 microspheres was 144 hs and for 1:2 TR/PLGA was 366 hs. The results of the in vivo experiments shown that the free TR not remain above the active for more than 24 days in both, aqueous and vitreous humors. For encapsulated TR/PLGA 1:1, the theoretical therapeutic level of 25µg/ml remained for up to 120 days. Conclusions: Micro–Taac demonstrated a more sustained in vitro and in vivo release profile than its free form. Taken together with its less traumatic implantation requirements, this system may characterize an optimized approach, overcoming most of the implantation barriers faced with the conventional pellet system.

Keywords: pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×